Ignite Creation Date:
2025-12-24 @ 8:03 PM
Ignite Modification Date:
2025-12-25 @ 5:36 PM
Study NCT ID:
NCT05540704
Status:
RECRUITING
Last Update Posted:
2025-10-21
First Post:
2022-09-09
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Study Comparing Acceptance and Commitment Therapy (ACT) to Supportive Diabetes Counseling for Problematic Eating and Weight Control in Type 1 Diabetes
Sponsor:
Duke University
Organization:
Study Overview
Official Title:
Changing the T1DE (Type 1 Disordered Eating): A Randomized Controlled Trial Comparing ACT to Supportive Diabetes Counseling
Status:
RECRUITING
Status Verified Date:
2025-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
T1DE
Brief Summary:
The goal of this study is to test the effectiveness of two different approaches to treating problematic eating and weight control in type 1 diabetes. Participants are between the ages of 16-50 and complete 12 sessions of either Acceptance and Commitment Therapy (ACT) or Supportive Diabetes Counseling over 16 weeks. They use their mobile phone between sessions to increase engagement and reinforce learning.
The main questions are:
Do participants show improvements in glycemic levels, eating disorder symptoms, diabetes management and diabetes distress?
Does one treatment do better than the other?
How do the treatments work, if they work, and for whom?
Participants complete assessments that include wearing a continuous glucose sensor and activity watch, and get a blood draw to determine HbA1c. They also complete diagnostic interviews, surveys and computer tests of attention and reactions. These assessments help us better understand the types of changes that are happening and how they might influence health and well-being.
The main questions are:
Do participants show improvements in glycemic levels, eating disorder symptoms, diabetes management and diabetes distress?
Does one treatment do better than the other?
How do the treatments work, if they work, and for whom?
Participants complete assessments that include wearing a continuous glucose sensor and activity watch, and get a blood draw to determine HbA1c. They also complete diagnostic interviews, surveys and computer tests of attention and reactions. These assessments help us better understand the types of changes that are happening and how they might influence health and well-being.
Detailed Description:
This is a randomized controlled trial comparing Acceptance and Commitment Therapy (ACT) to supportive diabetes counseling (SDC) for individuals with type 1 diabetes (T1D) and disordered eating (or T1DE). Both conditions are tailored to the unique needs of individuals living with T1D and the unique conditions under which an eating disorder develops and is maintained. Participants will be 128 individuals with T1D, between the ages of 16-50, with binge-purge eating disorders (EDs), including threshold and subthreshold bulimia nervosa, binge eating disorder and purging disorder. Purging includes restriction of insulin for weight loss. An expansion cohort of 58 persons with T1D and elevated Diabetes Eating Problems Survey-Revised scores (DEPS-R=\>20) will also be recruited to assess the utility of the protocol for a broader array of eating problems in T1D. Participants will be randomized to either ACT or SDC, and complete assessments at baseline, mid-treatment, end-of-treatment, 1 month, 3 months, and 6 months post-treatment. The primary outcome of interest for power and sample size calculation is mean blood glucose as assessed by continuous glucose monitoring. Other outcomes include hemoglobin A1c (HbA1c), eating disorder symptoms, diabetes self-management and, secondary, diabetes distress. In addition to examining clinical outcomes, this study tests biobehavioral mechanisms of change and predictors of treatment response. Process of change assessments focus on flexible responding to pathology-relevant stimuli and early improvement in glycemic control affecting executive function. The primary site is Duke University Medical Center. The Miriam Hospital is a secondary site.
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
Secondary ID Infos
| Secondary ID | Type | Domain | Link | View |
|---|---|---|---|---|
| 4-SRA-2022-1226-M-B | OTHER_GRANT | Breakthrough T1D (formerly JDRF) | View |